TECON BIOLOGYLTD 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hui Cheng

최고 경영자

CN¥600.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	17.9yrs
CEO 소유권	n/a
경영진 평균 재임 기간	13.2yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By TECON BIOLOGY Co.LTD's (SZSE:002100) Low P/S

Apr 12

CEO

Hui Cheng (59 yo)

17.9yrs

테뉴어

CN¥600,000

보상

Mr. Hui Cheng serves as General Manager and has been Director at Tecon Biology Co., Ltd. since December 20, 2006. Mr. Cheng is a senior veterinary surgeon.

리더십 팀

이름	위치	테뉴어	보상	소유권
Hui Cheng	GM & Director	no data	CN¥600.00k	데이터 없음
Lixin Geng	Financial Director	17.9yrs	CN¥300.00k	데이터 없음
Yubin He	Legal Director	8.7yrs	CN¥200.00k	데이터 없음
Yaxuan Huang	Human Resources Director	8.7yrs	CN¥250.00k	데이터 없음
Xiaowen Luo	Audit Director	no data	CN¥250.00k	데이터 없음
Heng Xu	Deputy GM & Director	no data	CN¥420.00k	데이터 없음
Yunjiang Guo	Board Secretary	17.7yrs	CN¥300.00k	데이터 없음
Jun Yang	Accounting Supervisor	no data	데이터 없음	데이터 없음

13.2yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 002100 의 관리팀은 노련하고 경험 (평균 재직 기간 13.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hui Cheng	GM & Director	17.9yrs	CN¥600.00k	데이터 없음
Heng Xu	Deputy GM & Director	6.7yrs	CN¥420.00k	데이터 없음
Jiang Liu	Member of Supervisory Board	8.7yrs	데이터 없음	데이터 없음
Haiying Dong	Non-Independent Director	1.8yrs	데이터 없음	데이터 없음
Kefeng Chen	Independent Director	1.8yrs	CN¥91.70k	데이터 없음
Gang Li	Independent Director	1.8yrs	CN¥91.70k	데이터 없음
Yonggang Qu	Independent Director	1.8yrs	CN¥91.70k	데이터 없음
Tao Zhang	Chairman of Supervisory Board	1.8yrs	데이터 없음	데이터 없음
Jie Zhang	Director	less than a year	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 002100 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

TECON BIOLOGYLTD 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

TECON BIOLOGY Co.LTD, Annual General Meeting, May 20, 2024

High number of new directors

TECON BIOLOGY Co.LTD, Annual General Meeting, May 19, 2023

TECON BIOLOGY Co.LTD Announces Executive Elections

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.041 loss in 3Q 2023)

TECON BIOLOGY Co.LTD (SZSE:002100) Could Be Riskier Than It Looks

TECON BIOLOGY Co.LTD to Report Q3, 2024 Results on Oct 29, 2024

TECON BIOLOGYLTD (SZSE:002100) Is Carrying A Fair Bit Of Debt

Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.34 loss in 2Q 2023)

Sentiment Still Eluding TECON BIOLOGY Co.LTD (SZSE:002100)

TECON BIOLOGY Co.LTD to Report First Half, 2024 Results on Aug 29, 2024

TECON BIOLOGYLTD (SZSE:002100) Is Making Moderate Use Of Debt

New minor risk - Financial position

TECON BIOLOGY Co.LTD, Annual General Meeting, May 20, 2024

Why Investors Shouldn't Be Surprised By TECON BIOLOGY Co.LTD's (SZSE:002100) Low P/S

TECON BIOLOGY Co.LTD to Report Q1, 2024 Results on Apr 30, 2024

TECON BIOLOGY Co.LTD to Report Fiscal Year 2023 Results on Apr 29, 2024

Third quarter 2023 earnings released: CN¥0.041 loss per share (vs CN¥0.28 profit in 3Q 2022)

High number of new directors

TECON BIOLOGY Co.LTD to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.02 loss in 2Q 2022)

TECON BIOLOGY Co.LTD Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 16 June 2023

Consensus EPS estimates fall by 13%

Tecon Biology Co.Ltd Approves Cash Dividend for the Year 2022

TECON BIOLOGY Co.LTD, Annual General Meeting, May 19, 2023

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.05 loss in 1Q 2022)

Price target decreased by 19% to CN¥10.90

TECON BIOLOGY Co.LTD Announces Executive Elections

Price target increased to CN¥15.17

Price target increased to CN¥13.44

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.43 loss in 3Q 2021)

Price target increased to CN¥13.44

Second quarter 2022 earnings released: CN¥0.02 loss per share (vs CN¥0.053 loss in 2Q 2021)

TECON BIOLOGY Co.LTD Approves Not to Pay Cash Dividend for 2021

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to CN¥14.70

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.43 loss per share (vs CN¥0.60 profit in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.053 loss per share (vs CN¥0.47 profit in 2Q 2020)

Consensus forecasts updated

Tecon Biology Co.Ltd Approves Cash Dividend for 2020

Price target decreased to CN¥20.35

Full year 2020 earnings released: EPS CN¥1.61 (vs CN¥0.60 in FY 2019)

TECON BIOLOGY Co.LTD to Report Fiscal Year 2020 Results on Apr 23, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥10.65

New 90-day low: CN¥12.40

New 90-day low: CN¥13.41

Third quarter earnings released

New 90-day low: CN¥13.92

New 90-day low: CN¥14.57

Earnings released

TECON BIOLOGY Co.LTD to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령